To expand on these findings, we developed a nanoparticulate liposome formulation that encapsulates the RA joint-specific, HLA-DRB1*04:01- and *01:01-restricted native self-peptide collagen II259-273 (CII) with the NF-κB inhibitor 1,25 dihydroxycholecalciferol (calcitriol), which targets dLN DCs. This evidence concerns the gene HLA-DRB1 and rheumatoid arthritis.